NCT00800319View on ClinicalTrials.gov

ALK33-001: A Study of RDC-0313 Administered to Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

June 30, 2009

Conditions
Alcohol Dependence
Interventions
DRUG

RDC-0313

Oral solution given in 5, 15, 25, 50, and 75 mg single doses

DRUG

Placebo

Volume matched placebo; oral solution; single dose

Trial Locations (1)

66211

Quintiles Phase One Services, Overland Park

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT00800319 - ALK33-001: A Study of RDC-0313 Administered to Healthy Adults | Biotech Hunter | Biotech Hunter